Facility Introduction for PD House Utsunomiya Hosoyacho, a nursing facility specializing in Parkinson's disease. Thoughts from the facility manager and staff, an…

When facing Parkinson's disease, patients and their families may eventually consider using a nursing facility. When choosing ...
AbbVie News Center

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

How far has regenerative medicine for Parkinson's disease progressed in Japan and overseas?

Research that won the 10th Bioindustry AwardOn July 15, 2026, Sumitomo Pharma Co., Ltd. and RACTHERA Inc. announced that the ...

BioVie Announces Update to Parkinson’s Phase 3 Development Program

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a ...
Today's Medical Developments

Developing more comfortable vibration therapy for patients with neurological disorders

Researchers redesign cumbersome medical equipment into a wearable platform.
Santé log

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally ...